Prevention of Macular Edema In Patients With Diabetic Retinopathy Undergoing Cataract Surgery

NCT01988246 ↗

Phase 1/2 Completed 30 enrolled Rishi Singh Regeneron Pharmaceuticals · collab

RandomizedParallel-groupSingle-blindPrevention

Summary

To determine the safety and efficacy of intravitreal Aflibercept (Eylea) injection in patients with diabetic retinopathy in the prevention of macular edema following cataract surgery.

Timeline

Start: 2013-12
Primary completion: 2018-04-25
Completion: 2020-01-14

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Aflibercept	Protein / enzyme biologic	2 mg	Intravitreal

Prevention of Macular Edema In Patients With Diabetic Retinopathy Undergoing Cataract Surgery

Summary

Timeline

Drugs

Indications